Welcome to our dedicated page for ADC Therapeutics SA news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on ADC Therapeutics SA stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage biotechnology company headquartered in Lausanne, Vaud, Switzerland. The company specializes in the development of antibody-drug conjugates (ADCs) to treat hematological malignancies and solid tumors. ADC Therapeutics is particularly known for its product ZYNLONTA® (loncastuximab tesirine-lpyl), which received accelerated approval from the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. ZYNLONTA is also under development for use in combination with other agents and for earlier lines of therapy.
The company has a broad portfolio of ADCs in various stages of clinical and preclinical development, including camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701, and ADCT-212. ADC Therapeutics leverages its proprietary technology to improve the treatment outcomes for cancer patients, focusing on both hematologic cancers and solid tumors.
In recent news, ADC Therapeutics announced several key updates, including the completion of dose escalation in their LOTIS-7 trial, which is evaluating ZYNLONTA in combination with bispecific antibodies for heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma. The company also presented promising data from a Phase 2 trial evaluating ZYNLONTA in patients with relapsed/refractory marginal zone lymphoma, showing high response rates and a good safety profile.
Financially, ADC Therapeutics reported ZYNLONTA net sales of $17.8 million for the first quarter of 2024 and continues to advance its hematology and solid tumor pipelines. The company has operations in London, the San Francisco Bay Area, and New Jersey. For more information, visit adctherapeutics.com and follow the company on LinkedIn.
PharmaVentures has announced the opening of a new office in Seoul, South Korea, as part of its strategic expansion to support Korean biopharma companies. JungHyun Eom will be based in Seoul, enhancing the firm's engagement with the rapidly growing Korean biotech sector. With over 30 years of experience, PharmaVentures has successfully facilitated over 40 transactions linking Western pharma with Korean innovators. The firm also collaborates with Korean government institutions and financial groups to bolster the global presence of the Korean biopharma industry.
ADC Therapeutics (NYSE: ADCT) has filed its Annual Report on Form 20-F with the SEC for the fiscal year ending December 31, 2022. This report is accessible on the SEC's website and the company's investor site. ADC Therapeutics is focused on advancing targeted antibody drug conjugates (ADCs), particularly ZYNLONTA, which is FDA-approved for treating relapsed or refractory diffuse large B-cell lymphoma. The company is also developing multiple ADCs in clinical and preclinical phases. Looking ahead, forward-looking statements highlight potential risks, including achieving sales guidance and managing operational expenses.
ADC Therapeutics (NYSE: ADCT) will have its CEO Ameet Mallik present at the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 7, 2023, at 2:50 p.m. ET. The presentation will be available via a live webcast on the company’s Investors page, with a replay accessible for 30 days afterwards.
ADC Therapeutics focuses on developing next-generation, targeted antibody drug conjugates for cancer treatment. Their CD19-directed ADC, ZYNLONTA, is FDA-approved for relapsed or refractory diffuse large B-cell lymphoma. The company is based in Lausanne, Switzerland, with operations in various locations including London and San Francisco.
FAQ
What is the current stock price of ADC Therapeutics SA (ADCT)?
What is the market cap of ADC Therapeutics SA (ADCT)?
What is the primary focus of ADC Therapeutics?
What is ZYNLONTA?
Where is ADC Therapeutics headquartered?
What recent developments has ADC Therapeutics announced?
What are some of the product candidates in ADC Therapeutics' pipeline?
How did ZYNLONTA perform financially in the first quarter of 2024?
Does ADC Therapeutics have international operations?
What are the strategic goals of ADC Therapeutics?
How can I learn more about ADC Therapeutics?
Who is the current Chief Executive Officer of ADC Therapeutics?
